These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31081036)

  • 1. Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir.
    Brooks KM; Castillo-Mancilla JR; Blum J; Huntley R; MaWhinney S; Alexander K; Kerr BJ; Ellison L; Bushman LR; MacBrayne CE; Anderson PL; Kiser JJ
    J Antimicrob Chemother; 2019 Aug; 74(8):2360-2364. PubMed ID: 31081036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
    MacBrayne CE; Marks KM; Fierer DS; Naggie S; Chung RT; Hughes MD; Kim AY; Peters MG; Brainard DM; Seifert SM; Castillo-Mancilla JR; Bushman LR; Anderson PL; Kiser JJ
    J Antimicrob Chemother; 2018 Aug; 73(8):2112-2119. PubMed ID: 29746648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic.
    Michal JL; Rab S; Patel M; Kyle AW; Miller LS; Easley KA; Kalapila AG
    AIDS Res Hum Retroviruses; 2018 Aug; 34(8):690-698. PubMed ID: 29766745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.
    Bunnell KL; Vibhakar S; Glowacki RC; Gallagher MA; Osei AM; Huhn G
    Pharmacotherapy; 2016 Sep; 36(9):e148-53. PubMed ID: 27459733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate.
    Brooks KM; Ibrahim ME; Castillo-Mancilla JR; MaWhinney S; Alexander K; Tilden S; Kerr BJ; Ellison L; McHugh C; Bushman LR; Kiser JJ; Hosek S; Huhn GD; Anderson PL
    J Antimicrob Chemother; 2019 Aug; 74(8):2352-2359. PubMed ID: 31093649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide.
    Custodio JM; Chuck SK; Chu H; Cao H; Ma G; Flaherty J; Ling J; Kearney BP
    Pharmacol Res Perspect; 2017 Oct; 5(5):. PubMed ID: 28971607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir.
    Brooks KM; Castillo-Mancilla JR; Morrow M; MaWhinney S; Blum J; Wyles DL; Rowan SE; Ibrahim ME; Zheng JH; Johnson B; Gomez J; Choi YJ; Cendali F; Haas H; Roon L; Bushman LR; Anderson PL; Kiser JJ
    J Antimicrob Chemother; 2020 Nov; 75(11):3303-3310. PubMed ID: 32766700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
    Lim JK; Liapakis AM; Shiffman ML; Lok AS; Zeuzem S; Terrault NA; Park JS; Landis CS; Hassan M; Gallant J; Kuo A; Pockros PJ; Vainorius M; Akushevich L; Michael L; Fried MW; Nelson DR; Ben-Ari Z;
    Clin Gastroenterol Hepatol; 2018 Nov; 16(11):1811-1819.e4. PubMed ID: 29306043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).
    Rosenthal E; Fougerou-Leurent C; Renault A; Carrieri MP; Marcellin F; Garraffo R; Teicher E; Aumaitre H; Lacombe K; Bailly F; Billaud E; Chevaliez S; Dominguez S; Valantin MA; Reynes J; Naqvi A; Cotte L; Metivier S; Leroy V; Dupon M; Allegre T; De Truchis P; Jeantils V; Chas J; Salmon-Ceron D; Morlat P; Neau D; Perré P; Piroth L; Pol S; Bourlière M; Pageaux GP; Alric L; Zucman D; Girard PM; Poizot-Martin I; Yazdanpanah Y; Raffi F; Pabic EL; Tual C; Pailhé A; Amri I; Bellissant E; Molina JM;
    HIV Med; 2018 Mar; 19(3):227-237. PubMed ID: 29214737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safety.
    Solas C; Bregigeon S; Faucher-Zaegel O; Quaranta S; Obry-Roguet V; Tamalet C; Lacarelle B; Poizot-Martin I
    Br J Clin Pharmacol; 2018 Feb; 84(2):404-409. PubMed ID: 29028125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study.
    Soeiro CASP; Gonçalves CAM; Marques MSC; Méndez MJV; Tavares APRA; Horta AMLMFCA; Sarmento-Castro RMDR
    BMC Infect Dis; 2018 Aug; 18(1):364. PubMed ID: 30075765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study.
    Barone M; Iannone A; Shahini E; Ippolito AM; Brancaccio G; Morisco F; Milella M; Messina V; Smedile A; Conti F; Gatti P; Santantonio T; Tundo P; Lauletta G; Napoli N; Masetti C; Termite AP; Francavilla R; Di Leo A; Pesce F; Andriulli A
    J Viral Hepat; 2018 Jan; 25(1):56-62. PubMed ID: 28787102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir.
    Townsend K; Petersen T; Gordon LA; Kohli A; Nelson A; Seamon C; Gross C; Tang L; Osinusi A; Polis MA; Masur H; Kottilil S
    AIDS; 2016 Jan; 30(2):261-6. PubMed ID: 26691547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01).
    Ingiliz P; Christensen S; Kimhofer T; Hueppe D; Lutz T; Schewe K; Busch H; Schmutz G; Wehmeyer MH; Boesecke C; Simon KG; Berger F; Rockstroh JK; Schulze zur Wiesch J; Baumgarten A; Mauss S
    Clin Infect Dis; 2016 Nov; 63(10):1320-1324. PubMed ID: 27535952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C.
    Keating GM
    Drugs; 2015 Apr; 75(6):675-85. PubMed ID: 25837989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.
    Balistreri WF; Murray KF; Rosenthal P; Bansal S; Lin CH; Kersey K; Massetto B; Zhu Y; Kanwar B; German P; Svarovskaia E; Brainard DM; Wen J; Gonzalez-Peralta RP; Jonas MM; Schwarz K
    Hepatology; 2017 Aug; 66(2):371-378. PubMed ID: 27997679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil Fumarate.
    Feng HP; Guo Z; Caro L; Talaty JE; Mangin E; Panebianco D; Fandozzi C; Zhu Y; Marshall W; Huang X; Hanley WD; Jumes P; Valesky R; Martinho M; Butterton JR; Iwamoto M; Yeh WW
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):962-970. PubMed ID: 31173674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans.
    Britnell SR; Willets AE; Vanderman AJ; Woodard CL; Britt RB
    Pharmacotherapy; 2016 Nov; 36(11):1173-1179. PubMed ID: 27716978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.
    Gane EJ; Hyland RH; Yang Y; Svarovskaia E; Stamm LM; Brainard DM; McHutchison JG; Stedman CAM
    Gastroenterology; 2017 May; 152(6):1366-1371. PubMed ID: 28137593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.
    Curry MP; Tapper EB; Bacon B; Dieterich D; Flamm SL; Guest L; Kowdley KV; Lee Y; Milligan S; Tsai N; Younossi Z; Afdhal NH
    Aliment Pharmacol Ther; 2017 Sep; 46(5):540-548. PubMed ID: 28691377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.